Rituximab: clinical development and future directions. - Wikidata - awgldk - TriplyDB

Rituximab: clinical development and future directions.

Rituximab: clinical development and future directions.

http://www.wikidata.org/entity/Q34482081

about

Myasthenia gravis: an update for the clinician.Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatm Therapeutic potential of antisense nucleic acid molecules.T cell-based therapies for EBV-associated malignancies.Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.Toxicity as a result of immunostimulation by biologics.Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine.Adverse consequences of immunostimulation.Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

P2860

Q34377145-3A1D13DD-1ACD-45E4-BD26-B75283CF8B86 Q35566338-92EF34CB-F75A-4306-9E44-20751AAE1895 Q35570262-F50F64BC-849B-4312-AFC7-DE9D1D2AB165 Q35609768-CADE35EE-4C29-46FE-B880-DFA6DF1C8C81 Q35641192-47D05BAD-7FA6-448B-93A5-2CB9906665CF Q36788414-A2971F9E-9CA5-4A9A-A9C9-660A269EF408 Q41555138-A9EFF2BB-6128-41E4-802C-8C8CE9BEB61D Q45289179-6FB45BC0-240D-4A31-87C4-0435ED909E4A Q45855065-4BBC89D8-17D2-4C54-912F-C6DB3D522157 Q55263277-40B6EA31-DC00-48BC-9659-64F9EA976567

P2860

Rituximab: clinical development and future directions.

http://www.wikidata.org/entity/Q34482081

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Rituximab: clinical development and future directions.

@ast

Rituximab: clinical development and future directions.

@en

Rituximab: clinical development and future directions.

@nl

type

label

Rituximab: clinical development and future directions.

@ast

Rituximab: clinical development and future directions.

@en

Rituximab: clinical development and future directions.

@nl

prefLabel

Rituximab: clinical development and future directions.

@ast

Rituximab: clinical development and future directions.

@en

Rituximab: clinical development and future directions.

@nl

P1433

Q34482081-7BABE82C-C8B0-419A-9DFC-0843845A14BD

P1476

Q34482081-C0FB2D67-245B-4684-B419-DC3782B0E992

P2093

Q34482081-F105AF6C-34B4-4ADB-8F8B-34E777F74578

P2860

Q34482081-22F01B64-7BA4-424E-A6ED-0A7BAC50B068

Q34482081-44417812-08A8-45F2-AB83-B89709C2DC9C

Q34482081-45E6AA3D-B081-4B2E-BE68-F40BD6C8DAEB

Q34482081-5582B1F5-1F94-44D7-8BE2-6006000D9EF7

Q34482081-562FC2B3-DADF-4424-ADA9-F26F80E1C06F

Q34482081-69348204-16DB-47BB-B2CF-79D043D6F33D

Q34482081-90B33E65-F666-4197-9FB4-16A70EB64B1D

Q34482081-AD96FED1-950A-4C2B-8F00-177F81950462

Q34482081-B1B10B75-6420-444B-9F1A-5B55D284A291

Q34482081-D3F0DBCC-63A8-4226-8274-35CA3EB85370

P304

Q34482081-4B729598-C454-473D-ADBC-7DF903968424

P31

Q34482081-1858E612-4534-4172-AA36-EA541BE389D2

P356

Q34482081-3296E560-DB2E-4689-A539-D89B9DCBF9E3

P407

Q34482081-E1D5B9FE-F8BF-4BDB-B11B-2F6E25D7C06C

P433

Q34482081-4CB66530-70FD-4BED-9E83-B95D7F1D1D86

P478

Q34482081-537B0DCA-681C-475C-B79A-787EB69A25A6

P577

Q34482081-AA63DF96-D12A-4715-AF49-491F28CDAC3E

P698

Q34482081-1532A50A-9EF2-4C18-9E84-E2A10E985476

P356

14712598.2.1.97

P1433

Expert Opinion on Biological Therapy

P1476

Rituximab: clinical development and future directions.

@en

P2093

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2001

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.

Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.

Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).

P304

97-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2.1.97

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11772344

http://www.w3.org/2001/XMLSchema#string